| 100 Years of Influenza: Pandemics and Practice: 1918-2018, part 2 J Auerbach, RE Besser, WH Foege, JP Koplan, JL Gerberding, ... | | |
| 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans MS Miller, T Tsibane, F Krammer, R Hai, S Rahmat, CF Basler, P Palese The Journal of infectious diseases 207 (1), 98-105, 2013 | 93 | 2013 |
| 20th international conference on emerging infectious diseases in the pacific rim organized by the United States-Japan cooperative medical sciences program (USJCMSP) USJCMSP AIDS, ARI, Cancer, Hepatitis, Immunology and Viral Diseases Panels Vaccines 7 (2), 35, 2019 | 1 | 2019 |
| 295 Autophagy as a basis for the health-promoting effects of vitamin D JN Tournier, M Mohamadzadeh, F Krammer, R Grabherr, WR Thomas, ... | | |
| 463 Treanor J, Webster RG, Garcia-Sastre A. 2018. Influenza F Krammer, GJD Smith, RAM Fouchier, M Peiris, K Kedzierska, ... Nat Rev Dis Primers 4 (3), 464, 0 | 2 | |
| A 10-minute “mix and read” antibody assay for SARS-CoV-2 J Rusanen, L Kareinen, L Levanov, S Mero, SH Pakkanen, A Kantele, ... Viruses 13 (2), 143, 2021 | 19 | 2021 |
| A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates F Krammer, I Margine, GS Tan, N Pica, JC Krause, P Palese Public Library of Science 7 (8), e43603, 2012 | 193 | 2012 |
| A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice R Nachbagauer, D Kinzler, A Choi, A Hirsh, E Beaulieu, N Lecrenier, ... npj Vaccines 1 (1), 1-10, 2016 | 74 | 2016 |
| A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the … CM Bliss, R Nachbagauer, C Mariottini, F Cuevas, J Feser, A Naficy, ... EBioMedicine 104, 2024 | 1 | 2024 |
| A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial R Nachbagauer, J Feser, A Naficy, DI Bernstein, J Guptill, EB Walter, ... Nature medicine 27 (1), 106-114, 2021 | 254 | 2021 |
| A correlate of protection for SARS-CoV-2 vaccines is urgently needed F Krammer Nature medicine 27 (7), 1147-1148, 2021 | 231 | 2021 |
| A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice S Strohmeier, F Amanat, JD Campbell, P Traquina, RL Coffman, ... npj Vaccines 7 (1), 81, 2022 | 7 | 2022 |
| A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin SS Paul, CK Mok, TM Mak, OW Ng, JO Aboagye, TJ Wohlbold, F Krammer, ... Antiviral research 144, 299-310, 2017 | 10 | 2017 |
| A HER2-displaying virus-like particle vaccine protects from challenge with mammary carcinoma cells in a mouse model L Nika, S Cuadrado-Castano, G Asthagiri Arunkumar, C Grünwald-Gruber, ... Vaccines 7 (2), 41, 2019 | 10 | 2019 |
| A high-throughput assay for circulating antibodies directed against the S protein of severe acute respiratory syndrome coronavirus 2 S Weiss, J Klingler, C Hioe, F Amanat, I Baine, S Arinsburg, EM Kojic, ... The Journal of infectious diseases 222 (10), 1629-1634, 2020 | 26 | 2020 |
| A live-attenuated prime, inactivated boost vaccination strategy with chimeric hemagglutinin-based universal influenza virus vaccines provides protection in ferrets: a … R Nachbagauer, F Krammer, RA Albrecht Vaccines 6 (3), 47, 2018 | 34 | 2018 |
| A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains F Broecker, STH Liu, N Suntronwong, W Sun, MJ Bailey, R Nachbagauer, ... npj Vaccines 4 (1), 31, 2019 | 50 | 2019 |
| A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice AW Freyn, JR da Silva, VC Rosado, CM Bliss, M Pine, BL Mui, YK Tam, ... Molecular Therapy 28 (7), 1569-1584, 2020 | 214 | 2020 |
| A Newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine W Sun, S McCroskery, WC Liu, SR Leist, Y Liu, RA Albrecht, S Slamanig, ... Vaccines 8 (4), 771, 2020 | 83 | 2020 |
| A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine (preprint) W Sun, S McCroskery, WC Liu, SR Leist, Y Liu, RA Albrecht, S Slamanig, ... | | 2020 |
Natalie PicaIcahn school of medicine at mount sinai在 mssm.edu 的电子邮件经过验证
Natalie PicaIcahn school of medicine at mount sinai在 mssm.edu 的电子邮件经过验证